Study backs Abbott's fetal lung development test:
This article was originally published in Clinica
Fears that Abbott Laboratories' fetal lung maturity test, which is performed on amniotic fluid collected from the vagina, may be affected by vaginal discharge, bacteria and mucus have been countered by a 153-patient US study. The TDx/TDxFLx fetal Lung Maturity II test, which has been in use for over five years, provides an accurate and non-invasive method for assessing fetal lung development, according to a team led by Rodney Edwards from the University of Florida College of Medicine. The findings were presented earlier this month at the Society for Maternal-Fetal Medicine meeting in Miami.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.